The 8-Bromo-cAMP sodium salt PKA activator, a synthetic analog of cAMP, is one of the most potent tools of investigating and playing with this pathway, which has become an essential part of ...

Background Middle-aged men seem to be particularly susceptible to adverse cardiovascular effects of endurance exercise. The ...

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

The secret to a healthier and "younger" heart lies in the vagus nerve. A recent study coordinated by the Sant'Anna School of ...

FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to ...

CYTK enters a new era as FDA approval of Myqorzo transforms it into a commercial biotech, opening a long-term growth runway in cardiology.

Cytokinetics has announced that the US Food and Drug Administration (FDA) has approved MYQORZO (aficamten) tablets in 5mg, ...

The FDA on Friday approved aficamten (Myqorzo) for symptomatic obstructive hypertrophic cardiomyopathy (HCM), drugmaker ...

Abstract: Studies of cardiovascular system have been the hot point generally concerned as well as extraordinarily significant issue of bioscience. Because of the complexity of cardiovascular system, ...

Abstract: Uterine mechanical behavior in the form of uterine contraction plays a key role in reproduction. Irregular patterns of uterine contractility associate with dysfunctions of the uterus.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO® (aficamten) has been approved by the China National Medical Products Administration (NMPA) for the treatment of adults with New ...

Objectives Patients with rheumatoid arthritis (RA) display an increased risk of heart failure independent of traditional cardiovascular risk factors. To elucidate myocardial disease in RA, we have ...